<DOC>
	<DOCNO>NCT00376623</DOCNO>
	<brief_summary>The trial perform evaluate whether BI 2536 may effective treatment advance metastatic NSCLC stage IIIB IV patient relapse failed first-line therapy . A secondary aim identify suitable dosage schedule Phase II III clinical programme BI 2536 . To achieve objective two dosage schedule compare .</brief_summary>
	<brief_title>Efficacy Safety BI 2536 Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>male female patient age 18 year old histologically cytologically confirm advanced metastatic NSCLC stage IIIB IV , relapse failed prior firstline chemotherapy advance metastatic disease . At least one tumour lesion must present accurately measure magnetic resonance imaging ( MRI ) , compute tomography ( CT ) least one dimension ( long diameter record ) 20 mm great conventional technique 10 mm great spiral CT scan . Life expectancy least three month ; Eastern cooperative oncology group ( ECOG ) performance score 2 less write informed consent must consistent international conference harmonisation good clinical practice ( ICHGCP ) local legislation persistence toxicity prior anti cancer therapy deem clinically relevant , know secondary malignancy require therapy , brain metastasis symptomatic require therapy , absolute neutrophil count less 1,500/mm3 , platelet count less 100,000/mm3 , haemoglobin le 9 mg/dl , aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great 2.5 time upper limit normal , AST ALT great 5 time upper limit normal case know liver metastasis , bilirubin great 1.5 mg/dl , serum creatinine great 2.0 mg/dl , concomitant intercurrent illness would limit compliance trial requirement consider relevant evaluation efficacy safety trial drug , chemo , hormone immunotherapy within past four week within less four halflife time previous drug prior treatment trial drug ( whatever long period ) , radiotherapy within past four week prior treatment trial drug , men woman sexually active unwilling use medically acceptable method contraception trial , pregnancy lactation , treatment investigational drug within past four week within less four halflife time investigational drug treatment trial drug ( whatever long period ) , patient unable comply protocol , patient consider eligible investigator secondline chemotherapy , radiotherapy immunotherapy , patient receive two line prior antitumour therapy advance metastatic non small cell lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>